Physician profile
Jeff C Wang
NPI 1558357988
$7,595.27
in general payments reported to CMS, 2019-2025
58 companies · $1,496 in 2025
The $1,496 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $515 · 2021: $634 · 2022: $717 · 2023: $1,180 · 2024: $1,616 · 2025: $1,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,887 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,886.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $404.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $762.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $652.73 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $629.71 | 2019-2025 | |
| Abbvie INC. | $584.62 | 2019-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $458.16 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi US Services INC. | $404.00 | 2024 | |
| Biotronik INC. | $369.88 | 2019-2024 | Amvia Edge, Biomonitor, Acticor 7 Vr-T Dx |
| Astrazeneca Pharmaceuticals LP | $365.39 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $289.91 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Astellas Pharma US INC | $283.93 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $244.14 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $239.69 | 2019-2025 | |
| Abbott Laboratories | $217.50 | 2020-2025 | Freestyle Libre 3, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.75 | 2019-2023 | Tradjenta, Synjardy, Jardiance |
| Esperion Therapeutics, INC. | $167.90 | 2021-2024 | Nexletol |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.